Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00532)
Name
Pimozide
Synonyms    Click to Show/Hide the Synonyms of This API
pimozide; 2062-78-4; Opiran; Pimozidum; Pimozidum [INN-Latin]; McN-JR-6238; R-6238; R 6238; UNII-1HIZ4DL86F; NSC 170984; McN-JR 6238; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1HIZ4DL86F; CHEMBL1423; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one; MLS000028410; MLS002702058; CHEBI:8212; MFCD00055081; NSC170984; NSC-170984; NCGC00015802-08; NCGC00015802-18; Primozida; SMR000058385; CAS-2062-78-4; DSSTox_CID_3474; 1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; DSSTox_RID_77042; DSSTox_GSID_23474; Primozida [INN-Spanish]; pimozida; Primozide; C28H29F2N3O; Pimozida [INN-Spanish]; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; CCRIS 9172; Orap (TN); SR-01000075392; EINECS 218-171-7; BRN 0729089; Prestwick_395; Pimozide [USAN:USP:INN:BAN:JAN]; Spectrum_000445; Tocris-0937; Opera_ID_1580; Prestwick0_000308; Prestwick1_000308; Prestwick2_000308; Prestwick3_000308; Spectrum2_001026; Spectrum3_001451; Spectrum4_000420; Spectrum5_001308; Lopac-P-1793; GTPL90; NCIMech_000356; P 1793; Lopac0_000946; SCHEMBL41584; BSPBio_000276; BSPBio_001439; BSPBio_002941; KBioGR_000720; KBioSS_000925; 5-24-02-00367 (Beilstein Handbook Reference); MLS001077311; BIDD:GT0435; DivK1c_000386; Methyl-(2-m-tolylethyl)amine; SPECTRUM1501134; Pimozide (JP17/USP/INN); SPBio_001211; SPBio_002495; BPBio1_000304; SCHEMBL7519553; DTXSID8023474; BCBcMAP01_000043; HMS501D08; KBio1_000386; KBio2_000925; KBio2_003493; KBio2_006061; KBio3_002441; AOB5780; NINDS_000386; HMS1568N18; HMS1791H21; HMS1921H19; HMS1989H21; HMS2089C11; HMS2092F09; HMS2095N18; HMS2231P23; HMS3262N14; HMS3267E19; HMS3370N13; HMS3402H21; HMS3411J16; HMS3675J16; HMS3712N18; Pharmakon1600-01501134; ZINC4175630; Tox21_110224; Tox21_301586; Tox21_500946; BDBM50334150; CCG-35918; CCG-36461; CCG-39728; NSC757854; 2-Benzimidazolinone, 1-[1-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-; 3-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidyl]-1H-benzimidazol-2-one; AKOS024458706; Tox21_110224_1; DB01100; LP00946; NSC-757854; SDCCGSBI-0050920.P004; IDI1_000386; SMP1_000241; NCGC00015802-01; NCGC00015802-02; NCGC00015802-03; NCGC00015802-04; NCGC00015802-05; NCGC00015802-06; NCGC00015802-07; NCGC00015802-09; NCGC00015802-10; NCGC00015802-11; NCGC00015802-12; NCGC00015802-13; NCGC00015802-14; NCGC00015802-15; NCGC00015802-16; NCGC00015802-26; NCGC00015802-29; NCGC00016601-01; NCGC00022282-03; NCGC00024888-01; NCGC00024888-02; NCGC00024888-03; NCGC00024888-04; NCGC00024888-05; NCGC00024888-06; NCGC00024888-07; NCGC00255294-01; NCGC00261631-01; AS-13916; HY-12987; SBI-0050920.P003; AB00052215; CS-0012921; EU-0100946; FT-0673903; SW196639-3; C07566; D00560; AB00052215-06; AB00052215_07; AB00052215_08; 062P784; 117210-EP2272537A2; 117210-EP2275420A1; 117210-EP2295061A1; 117210-EP2298776A1; L000494; Q144085; WLN: T56 BMVNJ D- DT6NTJ A3YR DF&R DF; J-013477; SR-01000075392-1; SR-01000075392-3; SR-01000075392-4; SR-01000075392-6; BRD-K01292756-001-06-0; BRD-K01292756-001-13-6; Pimozide, European Pharmacopoeia (EP) Reference Standard; Z241910386; 2-Benzimidazolinone,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-; N-benzyl-N-(3-isobutoxy-2-(pyrrolidin-1-yl)propyl)benzenamine; Pimozide, United States Pharmacopeia (USP) Reference Standard; 1-[1-[4,4-Bis(p-flurophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 2H-Benzimidazol-2-one,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-
Clinical Status
Approved
Disease Indication Schizophrenia ICD-11: 6A20 [1]
PubChem CID
16362
Formula
C28H29F2N3O
Canonical SMILES
C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
InChI
1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
InChIKey
YVUQSNJEYSNKRX-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=16362"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 461.5 Topological Polar Surface Area 35.6
XlogP 6.3 Complexity 632
Heavy Atom Count 34 Rotatable Bond Count 7
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Pimozide 1 mg tablet Click to Show/Hide the Full List of Formulation(s):          3 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Calcium stearate; Cellulose, microcrystalline; Starch, corn
                   Dosage Form Oral Tablet
                   Company Teva Select Brands
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Calcium stearate; Cellulose, microcrystalline; Starch, corn
                   Dosage Form Oral Tablet
                   Company Teva Select Brands
             Drug Formulation 3 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Calcium stearate; Cellulose, microcrystalline; Starch, corn
                   Dosage Form Oral Tablet
                   Company Par Pharmaceutical
          Pimozide 2 mg tablet Click to Show/Hide the Full List of Formulation(s):          2 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Calcium stearate; Cellulose, microcrystalline; Starch, corn
                   Dosage Form Oral Tablet
                   Company Teva Select Brands
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Calcium stearate; Cellulose, microcrystalline; Starch, corn
                   Dosage Form Oral Tablet
                   Company Avera McKennan Hospital; Par Pharmaceutical
References
1 FDA label for approved pimozide from the official website of the U.S. Food and Drug Administration.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.